Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03500302 · ClinicalTrials.gov registry record · Phase 2
Effect of Evolocumab on Coronary Endothelial Function
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT03500302: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT03500302 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03500302, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The investigators propose a pilot study using (1) MRI to assess coronary artery endothelial function, (2) brachial ultrasound to assess systemic endothelial function, (3) serum markers of inflammation and of endothelial cell function and (4) echocardiographic measures of left ventricular diastolic and systolic properties, before and following initiation of PCSK9 antibody in HIV positive subjects.
Interventions
- DRUG Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-05-04 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03500302
The ClinicalTrials.gov registry entry for NCT03500302 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Evolocumab is the first listed.
NCT03500302 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03500302 about?
NCT03500302 is a clinical study titled "Effect of Evolocumab on Coronary Endothelial Function". The investigators propose a pilot study using (1) MRI to assess coronary artery endothelial function, (2) brachial ultrasound to assess systemic endothelial function, (3) serum markers of inflammation and of endothelial cell function and (4) echocardiographic measures of left ventricular diastolic a...
What is the current status of trial NCT03500302?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-05-04. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT03500302?
The interventions under investigation include: Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03500302?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.